FDA Drug Approvals for Addiction Treatment
FDA guide for treatment center operators. MAT medication approvals, REMS requirements, and drug safety communications for behavioral health.
- Federal Agency
- FDA
Food and Drug Administration
The FDA approves medications used in addiction treatment including methadone, buprenorphine, and naltrexone for opioid use disorder.
At a Glance
- Type
- Federal Agency
- Acronym
- FDA
- Headquarters
- Silver Spring, MD
- Official Website
- Visit site ↗
- Parent Org
- U.S. Department of Health and Human Services
- Founded
- 1906
- Last Verified
- Mar 15, 2026
- Reading Time
- 6 min
Why This Matters
- Approves and regulates medications used in medication-assisted treatment
- Oversees REMS programs that affect how treatment facilities administer certain drugs
- Regulates drug safety labeling and prescribing information clinicians must follow
- Approves new treatment medications that expand clinical options for providers
- Issues safety alerts and recalls that affect facility formularies
Overview
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs, biological products, medical devices, and other regulated products. Established in 1906 with the passage of the Pure Food and Drugs Act and headquartered in Silver Spring, Maryland, the FDA is one of the oldest consumer protection agencies in the federal government. The agency operates within the U.S. Department of Health and Human Services with an annual budget exceeding approximately $6 billion as of 2025.
For behavioral health treatment facility operators, the FDA’s primary relevance lies in the agency’s role as the gatekeeper for medications used in addiction treatment. Every medication your prescribers use to treat substance use disorders — from buprenorphine and methadone for opioid use disorder to naltrexone and acamprosate for alcohol use disorder — has been evaluated and approved by the FDA through a rigorous review process. The FDA’s approval decisions, labeling requirements, safety communications, and Risk Evaluation and Mitigation Strategies directly affect your facility’s formulary, prescribing protocols, and medication management procedures.
The FDA also regulates drug testing products and medical devices used in treatment facilities, though these regulatory touchpoints are less prominent than medication regulation. Understanding the FDA’s role helps operators maintain compliant medication practices and stay informed about new treatment options as they move through the approval pipeline.
Why FDA Matters for Behavioral Health Providers
The medications the FDA approves define the pharmacological toolkit available to your prescribers. When the FDA approves a new addiction treatment medication or a new formulation of an existing one, it creates a new clinical option that may improve treatment outcomes, increase compliance, or reduce side effects. When the FDA issues safety restrictions or pulls a medication from the market, your facility must adapt its protocols accordingly.
Medication-assisted treatment for opioid use disorder illustrates the FDA’s central role. The three FDA-approved medications — methadone, buprenorphine, and naltrexone — represent the gold standard of care endorsed by SAMHSA, accreditors, and payers. Each medication went through FDA clinical trials that established its safety and efficacy. The FDA’s prescribing information for each medication generally defines the dosing parameters, contraindications, monitoring requirements, and patient counseling obligations your prescribers are expected to follow. Deviating from FDA-approved labeling can create both clinical risk and legal exposure.
The FDA’s REMS programs add another compliance layer for certain medications used in behavioral health settings. Buprenorphine products for opioid use disorder are subject to a shared REMS that includes prescriber education requirements. While the X-waiver requirement for buprenorphine prescribing was eliminated in 2022, the REMS requirements remain in effect. Your facility must ensure that prescribers meet applicable REMS training requirements and that medication distribution complies with REMS conditions.
New medication approvals represent both clinical opportunities and operational considerations. When the FDA approves a new treatment medication, your facility’s medical leadership needs to evaluate whether to add it to your formulary. This evaluation includes reviewing the clinical evidence, assessing cost implications, determining training needs for prescribing and administering staff, and updating clinical protocols. Staying current with the FDA approval pipeline helps you plan for these additions proactively.
Key Programs and Services
Center for Drug Evaluation and Research (CDER). CDER is the FDA division that evaluates and approves prescription and over-the-counter drugs, including medications used in addiction treatment. CDER reviews new drug applications, manages post-market safety surveillance, and regulates drug labeling. All FDA-approved medications in your facility’s formulary have been reviewed by CDER.
Medication-Assisted Treatment Approvals. The FDA has approved specific medications for substance use disorders: methadone, buprenorphine (in multiple formulations including sublingual tablets, sublingual film, buccal film, and subcutaneous implants and injections), and naltrexone (oral and extended-release injectable) for opioid use disorder; and naltrexone, acamprosate, and disulfiram for alcohol use disorder. Each approval carries specific indications, dosing information, and safety requirements.
Risk Evaluation and Mitigation Strategies (REMS). REMS are safety programs required by the FDA for medications with serious safety concerns that necessitate measures beyond standard labeling. The buprenorphine REMS includes requirements for prescriber education. Methadone distribution through OTPs has specific FDA regulatory requirements. Your facility must maintain compliance with all applicable REMS for medications it prescribes or dispenses.
Drug Safety Communications. The FDA publishes safety communications when new safety information emerges about approved medications. These communications may result in label changes, new warnings, dosing adjustments, or restrictions on use. Your facility needs a process for monitoring and responding to FDA safety communications that affect medications in your formulary.
MedWatch Adverse Event Reporting. The FDA’s MedWatch program collects reports of adverse events associated with FDA-regulated products. Treatment facilities should report serious adverse events related to medications used in treatment. Adverse event data informs the FDA’s post-market safety surveillance and can lead to safety communications or label changes.
How FDA Affects Your Facility
Formulary Management. The FDA’s approval decisions determine which medications are available for your formulary. When the FDA approves a new medication for a substance use disorder indication, your medical team should evaluate it for potential inclusion. When the FDA issues safety restrictions, your team must assess impact on current prescribing practices. Maintaining a formulary review process that incorporates FDA actions ensures your medication options remain current and compliant.
Prescribing Compliance. FDA-approved prescribing information defines how your prescribers should use each medication, including approved indications, dosing ranges, contraindications, drug interactions, and monitoring requirements. Prescribing outside FDA-approved parameters (off-label use) is legal in many contexts but creates documentation and liability considerations. Your facility should have clear policies regarding off-label prescribing, particularly for controlled substances.
REMS Compliance. If your facility prescribes or dispenses REMS-covered medications, compliance with all REMS requirements is mandatory. This includes ensuring prescribers complete required education, maintaining any required certifications, fulfilling patient counseling obligations, and adhering to distribution restrictions. Document REMS compliance activities for each applicable medication.
Medication Safety Monitoring. Establish a process for receiving and acting on FDA safety communications. Designate a staff member to monitor MedWatch alerts and other FDA communications. When a safety alert affects a medication in your formulary, document the review, any changes to prescribing protocols, and communication to affected clinical staff. Report serious adverse events through the MedWatch system.
Drug Testing Products. Urine drug screens and other drug testing products used in your facility are regulated by the FDA as diagnostic devices. Using FDA-cleared testing products and following manufacturer instructions for use helps ensure the accuracy of drug testing results, which are critical for clinical decision-making and may be used in legal proceedings.
Resources and Contact Information
Official Website: https://www.fda.gov ↗
MedWatch: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program ↗
Phone: (888) 463-6332 (888-INFO-FDA)
Mailing Address: Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993
Key Resources:
- FDA Approved Drug Products database (Drugs@FDA)
- MedWatch safety alerts and adverse event reporting
- REMS program information and compliance resources
- FDA guidance documents on opioid use disorder treatment
- Drug Safety Communications archive
- FDA labeling information for MAT medications
Frequently Asked Questions
This profile is provided for informational purposes only and does not constitute legal, regulatory, or professional advice. Information about this organization may change — always verify current details with official sources. is not affiliated with this organization unless otherwise stated.
Schedule a Demo
helps behavioral health organizations stay compliant, efficient, and connected to the organizations that matter.